Phantom Neuro develops the Phantom X, a minimally invasive implantable muscle-machine interface consisting of a subcutaneous sensor array with embedded electronics and proprietary machine-learning software that decodes electromyographic signals from residual limb muscles into real-time control commands for robotic prosthetics and exoskeletons. The company targets individuals with limb loss and mobility impairment, currently conducting clinical trials for upper limb prosthetic control. The Phantom X sensor is designed for outpatient implantation and integrates with commercially available robotic systems to enable multi-degree-of-freedom, intent-driven prosthetic control. Phantom Neuro received FDA Breakthrough Designation in 2026 and approval to conduct its first-in-human Early Feasibility Study (CYBORG) in Australia in April 2026. The company is led by physician Connor Glass. Phantom Neuro completed a seed funding round in September 2022 and is based in Austin, Texas.